State of Palestine
Diabetes country report 2011 — 2050
Skip Map
Number of adults (20–79 years) with diabetes in State of Palestine (PS)
| 2011 | 124.5 thousand |
| 2024 | 315.3 thousand |
| 2050 | 790.5 thousand |
State of Palestine is one of the 21 countries and territories in the IDF Middle-East and North Africa Region.
Data source(s) used for the diabetes estimates in adults:
- WHO STEPS 2010
- WHO STEPS 2021
2000
2011
2024
2050
Loading...
| Diabetes estimates (20-79 y) | ||||
|---|---|---|---|---|
| People with diabetes, in 1,000s | - | 124.5 | 315.3 | 790.5 |
| Age-standardised prevalence of diabetes, % | - | 9.2 | 15.5 | 17.5 |
| Proportion of people with undiagnosed diabetes, % | - | - | 30.2 | - |
| People with undiagnosed diabetes, in 1,000s | - | - | 95.2 | - |
| Impaired Fasting Glucose (IFG) | ||||
|---|---|---|---|---|
| People with IFG, in 1,000s | - | - | 163.9 | 350.6 |
| Age-standardised prevalence of IFG, % | - | - | 6.4 | 6.7 |
| Impaired Glucose Tolerance (IGT) | ||||
|---|---|---|---|---|
| People with IGT, in 1,000s | - | 77.4 | 120.6 | 281.1 |
| Age-standardised prevalence of IGT, % | - | 5.3 | 5.6 | 5.9 |
| Mortality attributable to diabetes (20-79 y) | ||||
|---|---|---|---|---|
| Deaths attributable to diabetes | - | - | 2,722.7 | - |
| Proportion of diabetes-related deaths in people 20-79 y, % | - | - | 13.6 | - |
| Hyperglycaemia in pregnancy (HIP) (20-49 y) | ||||
|---|---|---|---|---|
| Live births affected by HIP | - | - | - | - |
| Prevalence of gestational diabetes mellitus (GDM), % | - | - | - | - |
| Live births affected by other types of diabetes first detected in pregnancy | - | - | - | - |
| Live births affected by other types of diabetes detected prior to pregnancy | - | - | - | - |
| Diabetes-related health expenditure | ||||
|---|---|---|---|---|
| Total diabetes-related health expenditure, USD million | - | - | - | - |
| Total diabetes-related health expenditure, ID million | - | - | - | - |
| Diabetes-related health expenditure per person, USD | - | - | - | - |
| Diabetes-related health expenditure per person, ID | - | - | - | - |
| Type 1 diabetes estimates in children and adolescents | ||||
|---|---|---|---|---|
| People with type 1 diabetes (all age groups) | - | - | 10,958.0 | - |
| People with type 1 diabetes (0-19 y) | - | - | 3,657.3 | - |
| Demographics | ||||
|---|---|---|---|---|
| Total adult population (20-79 y), in 1,000s | - | 1,896.0 | 2,807.7 | 5,532.8 |
| Population of children and adolescents (0-19 y) | - | - | 2,655,785.5 | - |
Loading...
| Diabetes estimates (20-79 y) | |
|---|---|
| People with diabetes, in 1,000s | - |
| Age-standardised prevalence of diabetes, % | - |
| Proportion of people with undiagnosed diabetes, % | - |
| People with undiagnosed diabetes, in 1,000s | - |
| Impaired Fasting Glucose (IFG) | |
|---|---|
| People with IFG, in 1,000s | - |
| Age-standardised prevalence of IFG, % | - |
| Impaired Glucose Tolerance (IGT) | |
|---|---|
| People with IGT, in 1,000s | - |
| Age-standardised prevalence of IGT, % | - |
| Mortality attributable to diabetes (20-79 y) | |
|---|---|
| Deaths attributable to diabetes | - |
| Proportion of diabetes-related deaths in people 20-79 y, % | - |
| Hyperglycaemia in pregnancy (HIP) (20-49 y) | |
|---|---|
| Live births affected by HIP | - |
| Prevalence of gestational diabetes mellitus (GDM), % | - |
| Live births affected by other types of diabetes first detected in pregnancy | - |
| Live births affected by other types of diabetes detected prior to pregnancy | - |
| Diabetes-related health expenditure | |
|---|---|
| Total diabetes-related health expenditure, USD million | - |
| Total diabetes-related health expenditure, ID million | - |
| Diabetes-related health expenditure per person, USD | - |
| Diabetes-related health expenditure per person, ID | - |
| Type 1 diabetes estimates in children and adolescents | |
|---|---|
| People with type 1 diabetes (all age groups) | - |
| People with type 1 diabetes (0-19 y) | - |
| Demographics | |
|---|---|
| Total adult population (20-79 y), in 1,000s | - |
| Population of children and adolescents (0-19 y) | - |
